Immuron picks new director
Immuron (ASX:IMC) has appointed Stephen Anastasiou as its latest non-executive director.
Anastasiou’s career in the healthcare industry has spanned more than 20 years, focusing on general management, marketing and strategic planning.
He has had roles including management consultant at KPMG Peat Marwick (now KPMG) and a management position at international pharmaceutical company Bristol Myer Squibb.
Anastasiou is currently a director and shareholder of a number of unlisted companies in healthcare and other sectors.
Immuron has developed Travelan, an OTC treatment for travellers’ diarrhoea. In 2011, the company scored a licensing deal for the product with distributor Paladin Labs worth up to $115 million. The company is also developing a treatment for hospital superbug C. difficile.
Immuron shares were trading unchanged at $0.004 as of around 1 pm on Wednesday.
Cancer drug eliminates bone metastasis in lab models
Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...
TGA rejects Alzheimer's drug due to safety concerns
The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
